SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
Key Highlights
- ➤SeaStar Medical (ICU) seeks approximately $3.3 million through discounted warrant exercises
- ➤854,002 warrants repriced to $3.866 per share from $6.38-$7.62
- ➤SeaStar Medical will issue new warrants covering 1,708,004 shares at $3.616
- ➤New warrants include five-year and eighteen-month tranches, both immediately exercisable
- ➤Net proceeds target general corporate purposes, including working capital and capital expenditures
DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical’s common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the “Prior Warrants”), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggregate gross proceeds of approximately $3.3 million, before deducting placement agent fees and other offering expenses. The shares of common stock issuable upon the exercise of the Prior Warrants are registered pursuant to effective registration statements on Form S-1 (Nos. 333-288065 and 333-289447).
Get started
Create a free account to read the full story.